Abstract
Background
The ongoing effort to prevent dialysis-related amyloidosis (DRA) has been hampered by lack of any way to measure DRA’s severity. Yet, such measurement is essential for assessing the effect of DRA treatment. Accordingly, we developed a scoring system focused on the physical manifestations of DRA.
Methods
Forty-four patients on maintenance hemodialysis with DRA, and 96 without it, were enrolled. The SF-36v2 Health Survey ascertained whether patients experienced general bodily pain and/or physical dysfunction with any attendant specific pain (dysfunction). If so, the association of those conditions with a finding of DRA was analyzed—including laboratory and radiographic data—and a scoring system reflecting the extent of that dysfunction was devised using the significant variables in the multivariate analysis.
Results
Both dysfunction and general bodily pain were severe in patients with DRA. Presence of polyarthralgia, trigger finger, carpal tunnel syndrome (CTS), and dialysis-related spondyloarthropathy (DRS) were associated with that dysfunction after appropriate adjustments. The new scoring system used those four variables in the model, with a 3 given for polyarthralgia and DRS, and 2 for trigger finger and CTS (possible range 0–10). Based on the physical functioning score of SF-36v2, we categorized A-score into three stages: mild (A-score 3–4), moderate (5–7), and severe (8–10). The corresponding area under the receiver-operating characteristics curve for diagnosis of DRA was 0.9345 when we set the cutoff value as 4.
Conclusion
This validated scoring system for quantitatively estimating the severity of DRA can serve as A useful measure in clinical practice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hoshino J, Yamagata K, Nishi S, Nakai S, Masakane I, Iseki K, et al. Carpal tunnel surgery as proxy for dialysis-related amyloidosis: results from the Japanese society for dialysis therapy. Am J Nephrol. 2014;39(5):449–58.
Kuragano T, Inoue T, Yoh K, Shin J, Fujita Y, Yoshiya K, et al. Effectiveness of beta(2)-microglobulin adsorption column in treating dialysis-related amyloidosis: a multicenter study. Blood Purif. 2011;32(4):317–22.
van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J. Effect of dialysis membrane and patient’s age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int. 1991;39(5):1012–9.
Busch M, Schwenzky A, Franke S, Stein G, Wolf G. Advanced glycation end products and beta(2)-microglobulin as predictors of carpal tunnel syndrome in hemodialysis patients. Blood Purif. 2012;34(1):3–9.
Abe T, Uchita K, Orita H, Kamimura M, Oda M, Hasegawa H, et al. Effect of beta(2)-microglobulin adsorption column on dialysis-related amyloidosis. Kidney Int. 2003;64(4):1522–8.
Fukuhara S, Suzukamo Y. Manual of SF-36v2, Japanese version. Kyoto: Institute for Health Outcomes and Process Evaluation research; 2004.
Kiss E, Keusch G, Zanetti M, Jung T, Schwarz A, Schocke M, et al. Dialysis-related amyloidosis revisited. AJR Am J Roentgenol. 2005;185(6):1460–7.
Theodorou DJ, Theodorou SJ, Resnick D. Imaging in dialysis spondyloarthropathy. Semin Dial. 2002;15(4):290–6.
Nokura K, Koga H, Yamamoto H, Kimura A, Tamai H, Yazaki S, et al. Dialysis-related spinal canal stenosis: a clinicopathological study on amyloid deposition and its AGE modification. J Neurol Sci. 2000;178(2):114–23.
Nishi S, Ubara Y. Dialysis-related amyloidosis [article in Japanese]. Tokyo: Ishiyaku Publishers, Inc.; 2011.
Otsubo S, Kimata N, Okutsu I, Oshikawa K, Ueda S, Sugimoto H, et al. Characteristics of dialysis-related amyloidosis in patients on haemodialysis therapy for more than 30 years. Nephrol Dial Transplant. 2009;24(5):1593–8.
Steyerberg EW. Clinical prediction models. New York: Springer; 2010.
Drent G, Graveland CW, Hazenberg BP, Haagsma EB. Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation. Amyloid. 2009;16(3):133–41.
Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 2004;104(6):1888–93.
Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26(11):1346–53.
Nakai S, Hanafusa N, Masakane I, Taniguchi M, Hamano T, Shoji T, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2012). Ther Apher Dial. 2014;18(6):535–602.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None of the authors declare any conflict of interest.
Human and animal rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (IRB approval number 636) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Funding source
This study was supported in part by J.H.’s research Grant from the Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japanese Association of Dialysis Physicians (JADP Grant 2015-10), and in part by K.T.’s Grant-in-Aid for Amyloidosis research, Research on Intractable Disease, from the Ministry of Health, Labor, and Welfare of Japan (H23-intractable-general-012).
About this article
Cite this article
Hoshino, J., Kawada, M., Imafuku, A. et al. A clinical staging score to measure the severity of dialysis-related amyloidosis. Clin Exp Nephrol 21, 300–306 (2017). https://doi.org/10.1007/s10157-016-1287-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-016-1287-3